| Field | Specification |
|---|---|
| Target | |
| Alternative names | Retinol-binding protein 4;Plasma retinol-binding protein;PRBP;RBP;Plasma retinol-binding protein (1-182);Plasma retinol-binding protein (1-181);Plasma retinol-binding protein (1-179);Plasma retinol-binding protein (1-176);RBP4;PRO2222; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human RBP4 recombinant protein (Position: E19-201L). Human RBP4 shares 86% amino acid (aa) sequence identity with both mouse and rat RBP4. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects retinol-binding protein 4 (gene RBP4) in human samples and is validated for ELISA, ICC/IF, IHC and Western blot. The predicted molecular weight is 23.0 kDa, and the supplier reports an observed band at about 23 kDa.
Retinol-binding protein 4 (RBP4) is the main plasma carrier of vitamin A. Produced mostly by the liver, it transports retinol in blood, often in complex with transthyretin, and delivers it to tissues through the receptor STRA6. RBP4 is also released by fat tissue and is measured in studies of vitamin A status, insulin resistance and metabolic disease.
| Target | Retinol-binding protein 4 (gene RBP4; UniProt P02753, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 23.0 kDa |
| Observed MW | 23 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human hepatocellular carcinoma paracancerous tissue (HCCP).
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 13% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): human liver cancer tissue.
Immunogen
E. coli-derived human RBP4 recombinant protein (Position: E19–201L). Human RBP4 shares 86% amino acid (aa) sequence identity with both mouse and rat RBP4.
Reactivity Notes
The supplier lists reactivity with human. UniProt describes retinol-binding protein 4 as a secreted protein. Tissue expression noted by UniProt (human): Detected in blood plasma and in urine (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
